

Company statement

Grifols begins phased reopening of its plasma donation centres in Canada

October 20, 2026

Grifols has begun a phased resumption of plasma collection activities at its Canadian donation centres, in alignment with Health Canada. The first two centres reopening today are Innovation Drive in Winnipeg and Windermere in Edmonton, as part of a reopening plan developed in coordination with Health Canada and Canadian Blood Services. Both centres will initially operate with a reduced number of daily donor appointments, which will increase gradually over time. Additional locations across the network will reopen progressively.

On August 14, Grifols proactively and voluntarily paused plasma collection activities at all its donation centres in Canada. Since then, the centres have remained closed to the public but operational, with employees continuing to perform the operational, quality control, training and readiness activities required to support reopening.

During this period, the company has strengthened operating procedures, documentation practices, employee training and supervision, staffing models, quality review processes and operational oversight throughout its Canadian donation centre network. Grifols also accelerated the acquisition of the remaining ownership interest in Canadian Plasma Resources (now Grifols Canada Plasma Inc.), the company that managed most of its Canadian donation centres, and assumed full operational control on September 1, strengthening alignment across its Canadian operations.

Grifols continues to work closely and collaboratively with Health Canada on the phased reopening of additional centres and remains committed to maintaining the highest standards of quality, donor safety, regulatory compliance and operational excellence.

More than 10,000 Canadians rely on plasma-derived medicines each year. Since Grifols began its partnership with Canadian Blood Services in 2022, Canada's domestic immunoglobulin sufficiency has more than doubled, from 15 percent to 34 percent by the end of 2025. Plasma collected by Grifols in Canada is reserved for Canadian Blood Services and Canadian patients.

Grifols is committed to building a stronger, more self-sufficient plasma medicines system for Canadian patients. The company has invested more than C\$1 billion in Canada, including in the development of a plasma manufacturing facility in Montréal, supports close to 800 permanent jobs and operates a nationwide network of 17 plasma donation centres.